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Aims: Venous thromboembolism (VTE) is the most common preventable cause of hospital-related
mortality. There are major inadequacies internationally in administering appropriate prophylaxis. Our
initial aim was to show whether our local effectiveness of administration was equally poor. With local
inadequacy conﬁrmed, our second aim was to design, implement and evaluate the efﬁcacy of a new VTE
protocol nested within a surgical clerking proforma.
Methods: A pilot audit of the prescription and administration of enoxaparin and thromboembolic
deterrent stockings for VTE prophylaxis in 51 acutely admitted surgical inpatients (Round 1) was per-
formed against local guidelines derived from the American College of Chest Physicians (ACCP) criteria.
The authors then designed and implemented a VTE prevention protocol incorporating risk assessment
and decision support within a new clerking proforma for acute surgical admissions. Local practice was
audited against the same criteria in Round 2, which comprised 60 consecutive acute surgical admissions
in the same district general hospital.
Results: In the pilot study, only (19/51) 37% of subjects received appropriate VTE prophylaxis. Over half of
patients were at high risk for VTE; 18/29 high risk patients and 4/10 medium risk patients were not
adequately protected. Following implementation of the quality improvement intervention, (53/60) 88%
of subjects received appropriate prophylaxis (p < 0.001).
Conclusions: Implementation of a VTE protocol as part of a clerking proforma for acute surgical
admissions is a simple and effective way of ensuring that surgical patients receive appropriate throm-
boprophylaxis. A similar strategy could be employed to broaden the scope of the National Institute of
Clinical Excellence (NICE) guidelines to address VTE prevention in all hospitalised patients.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Venous thromboembolism (VTE) is the most common
preventable cause of hospital-related mortality,1,2 accounting for
10% of deaths in UK hospitals.3 In the absence of appropriate
prophylaxis, the incidence of deep vein thrombosis (DVT) in general
surgical patients may be as high as 40%.1 Although there is over-
whelming clinical and economic evidence for the efﬁcacy of VTE
prophylaxis in patients at risk, only about a third of those receive
appropriate prophylaxis.4 At the time of publication there are major
inadequacies in the international administration of appropriate
VTE prophylaxis.3,5–7
Prophylaxis against VTE has already been ranked the most
important safety practice in American healthcare.2 The scope of
current UK NICE guidelines8 for VTE prophylaxis is limited tont of Radiology, Cambridge
ad, Cambridge CB2 2QQ, UK.
ciates Ltd. Published by Elsevier Ltpatients undergoing surgery, yet a large proportion of acute
surgical admissions are at high risk of VTE prior to surgical proce-
dures. Many surgical patients who do not undergo operations are
also at risk. It has therefore been widely recommended that all
hospitalised patients should be assessed for risk of VTE and treated
accordingly.6 Despite this recommendation, there are no national
guidelines for VTE prevention in surgical patients based on their
underlying risk factors before surgery.
While many distinct factors contribute to VTE risk, there is little
formal understanding of how the various risk factors interact to
determine the position of each patient along a continuous spec-
trum of thromboembolic risk. Consequently, any individualised VTE
score is of uncertain beneﬁt. Such an approach has not been sub-
jected to rigorous clinical evaluation; it is logistically complex and
is likely to be associated with sub-optimal compliance. The seventh
American College of Chest Physicians (ACCP) Conference therefore
proposed implementation of standard group-speciﬁc prophylaxis
in 3–4 deﬁned risk-stratiﬁed groups.9
We undertook an audit of the appropriate prescription and
administration of pharmacological and mechanical VTEd. All rights reserved.
Table 1
The Seventh American College of Chest Physicians (ACCP) Consensus Conference on
Antithrombotic Therapy8 recommends that patients are classiﬁed as having low,
moderate, high, and very high risks for the development of venous thromboem-
bolism and that the prophylactic regimens are used according to this risk
stratiﬁcationa.
Level of risk Successful prevention strategies
Low risk – minor surgery in patients aged
<40 with no additional risk factors
No speciﬁc prophylaxis; early and
‘‘aggressive’’ mobilisation
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or thromboembolic deterrent (TED) stockings) in 51 patients
admitted acutely to a district general hospital under the care of the
surgical team. We then designed a VTE prevention protocol incor-
porating risk assessment and decision support within a new
clerking proforma for acute surgical admissions. Following imple-
mentation of the new clerking proforma, local practice was
re-audited against the same criteria as before.Moderate risk – minor surgery in patients
with additional risk factors; surgery in
patients aged 40–60 with no
additional risk factors
Low-molecular-weight heparin (3400 U
daily), graduated compression stockings,
or intermittent pneumatic compression
High risk – surgery in patients aged >60,
or aged 40–60 with additional risk
factors (prior VTE, cancer, molecular
hypercoagulability)
Low-molecular-weight heparin (>3400 U
daily), or intermittent pneumatic
compression
Highest risk – surgery in patients with
multiple risk factors (age >40, cancer,
prior VTE), hip or knee arthroplasty,
major trauma
Low-molecular-weight heparin (>3400 U
daily), fondaparinux, warfarin (INR, 2–3),
or intermittent pneumatic compression/
graduated compression stockings þ low-
dose unfractionated heparin/low-
molecular-weight heparin
a Adapted from 2004 ACCP consensus conference.
Table 2
Rates of appropriate VTE prophylaxis prescription in Round 1, stratiﬁed according to
patients’ risk status.
Low
risk
Medium
risk
High
risk
Total
Number of patients 12 10 29 51
Number of patients who received appropriate
prescriptions for VTE prophylaxis
2 6 11 192. Round 1
2.1. Materials and methods
The audit was carried out in Hinchingbrooke NHS Trust Hospital,
Huntingdon in the UK – a district general hospital with 396 beds.
Annually, 33,000 patients attend the emergency department and
there are approximately 30,000 inpatient and day case admissions.
On the general surgical take, patients are admitted under the care
of one of the surgical teams. There are two colorectal consultants,
one breast consultant and three upper GI consultants. There are
two specialist registrars who each spend 1 year on a rotation in the
department, and ﬁve staff grade surgeons.
Inclusion criteria for the study were all patients admitted
acutely under the care of the surgical team between 25/11/07 and
17/12/07. Exclusion criteria were children (age < 18). Data were
collected prospectively by two observers (GM and AK) by exam-
ining the case notes, prescription charts and by direct examination
of patients no more than 24 h after admission.
The following data were obtained for each subject: age, the
presence of any contraindications to pharmacological prophylaxis
(i.e. active bleeding, potentially bleeding lesion, uncorrected
bleeding disorder, anticoagulated or on treatment dose of enox-
aparin, hypersensitivity to enoxaparin) or mechanical prophylaxis
(i.e. peripheral arterial disease), the presence of the following risk
factors: obesity (body mass index > 30), immobility for 3 days or
more (including post major surgery or trauma), a previous history
of VTE, varicose veins or phlebitis, malignancy, thrombophilia,
pregnancy or within the puerperium. In addition, we documented
whether patients had been prescribed thromboembolic deterrent
(TED) stockings and whether they had been ﬁtted. The prescription
charts were examined to see if enoxaparin had been prescribed and
what dose (20 or 40 mg) was given.
Primary outcome measures:
 Proportion of appropriate pharmacological VTE prophylaxis
prescribed. This was measured using a standardised protocol
derived from ACCP recommendations (Table 1).
 Delay in any prescription of pharmacological VTE prophylaxis.
 Administration of appropriate mechanical VTE prophylaxis.
This studywas approved prior to initiation by the local audit and
ethics committee.Table 3
Risk factors for VTE in Round 1 subjects.
Number of patients
Age > 40 36
Immobility  3 days 14
Cancer 12
Obesity (BMI > 30) 7
Previous history of VTE 6
Thrombophilia 0
Pregnancy/puerperium 0
Varicose veins/phlebitis 02.2. Results of Round 1
Of the 51 subjects who met the inclusion criteria for this pilot
study, only 19 (37%) were prescribed appropriate prophylaxis. The
distribution of these prescriptions with respect to their VTE risk is
illustrated in Table 2. The vast majority of surgical admissions had
explicit risk factors for VTE. In Round 1 29/51(57%) were in the high
risk category and a further 10/51 (20%) were assessed to have
medium risk. Alarmingly, 18/29 high risk patients and 4/10medium
risk patients were not prescribed adequate prophylaxis. The inci-
dence of VTE risk factors is shown in Table 3. Nine (18%) patients
had contraindications to pharmacological prophylaxis (Table 4).Delay to prescription of pharmacological prophylaxis was also
analysed. Of the 36 patients who were prescribed enoxaparin, only
24 (67%) prescriptions were ordered on the day of admission.
All 51 subjects in the studywere eligible for prescription of TEDS
but only 34 subjects (67%) had them prescribed on the prescription
chart and 19 (37%) had them ﬁtted.
No signiﬁcant difference in the prescribing rates of the indi-
vidual specialities was noted.2.3. Action after results of Round 1
The ﬁndings of the ﬁrst round audit were presented to the
Hinchingbrooke Hospital Trust Surgical Clinical Governance
meeting and agreement reached about the need to improve VTE
prophylaxis. A new, simpliﬁed VTE protocol, based on the ACCP
guidelines, was designed by the authors (Table 5) and nestedwithin
a novel surgical clerking proforma. It was approved by the surgical
department and implemented for all acute surgical admissions. The
importance of VTE risk stratiﬁcation was explained to all surgical
staff and education delivered to attendees.
Table 4
Contraindications to pharmacological VTE prophylaxis in Round 1 subjects.
Number of patients
Anticoagulated or on treatment dose of enoxaparin 4
Potentially bleeding lesion 3
Active bleeding 2
Uncorrected bleeding disorder 0
Hypersensitivity to enoxaparin 0
Table 5
Simpliﬁed VTE protocol incorporated within surgical clerking proforma – modiﬁed
from Geerts et al9.
VTE risk assessment protocol (circle as appropriate)
Age > 40 Varicose veins/thrombophlebitis
Obesity (BMI > 30) Thrombophilia
Cancer Pregnancy/puerperium
Previous DVT/PE Other:
Immobilisation  3 days
Contraindication to prophylaxis? Yes/No (specify):
No. of risk factors 0 1 2 or more
Risk level Low Medium High
Prescription of
VTE prophylaxis
TEDS TEDS þ 20 mg
enoxaparin
TEDS þ 40 mg
enoxaparin
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3.1. Materials and methods
Inclusion criteria for the repeat study were all acute surgical
admissions between 11/1/08 and 28/1/08. Medical staff were
unaware that their prescriptions were being audited and data were
collected prospectively by the same two observers.
The same data as in Round 1were obtained between 12 and 24 h
after admission (see Section 2.1) and the same primary outcome
measures were used. Sixty acute surgical admissions met the
criteria for the follow-up study after implementation of the VTE
protocol.
3.1.1. Statistics
The Fisher Exact Test was used to compare the rates of appro-
priate prescription of VTE prophylaxis between Rounds 1 and 2. The
null hypothesis was that implementation of the new VTE protocol
and presentation of the results at the Surgical Clinical Governance
meeting would not alter the subsequent rate of appropriate
prescription.
3.2. Results of Round 2
The rate of appropriate prescription of VTE prophylaxis was
found to be signiﬁcantly improved, with 53/60 (88%) subjects
receiving appropriate prescriptions (Table 6). Six (10%) patients had
contraindications to pharmacological thromboprophylaxis and one
had contraindication to mechanical prophylaxis. Of the seven
patients who were not prescribed appropriate prophylaxis, six had
not been ﬁltered through the surgical assessment proforma. Of
these seven patients whowere not adequately protected, four wereTable 6
Comparison of Round 1 and Round 2.
No. of inappropriate prescriptions No. of appropriate prescriptions
Round 1 32 19
Round 2 7 53
p < 0.001.high risk, two were medium risk and one was low risk for VTE. The
single patient who was ﬁltered though the clerking proforma yet
did not receive appropriate prophylaxis was in the high risk group
for VTE but received only 20 mg of enoxaparin. In this case the
proforma was used to record the admission clerking, but the risk
assessment tool was not completed.4. Discussion
The pilot study (Round 1) deﬁned the extent of the shortfall in
prescription of VTE prophylaxis in acute surgical admissions. Only
19 out of 51 subjects (37%) received appropriate prophylaxis. Of
these 51 subjects, 29 (57%) were classiﬁed as high risk for VTE.
Alarmingly, we found lower rates of appropriate prescription of
prophylaxis in this subgroup. These ﬁndings mirror those of the
ENDORSE multinational cross-sectional study published in
February 20087 and demonstrate our local incidence of this inter-
nationally recognised problem.
Following implementation of the quality improvement inter-
vention, a signiﬁcant improvement was noted upon re-audit of
appropriate VTE prophylaxis rates. Fifty-three out of 60 (88%)
subjects had received the appropriate prophylaxis.
We believe that the effectiveness of this new VTE protocol in
improving rates of appropriate prophylaxis in our acute surgical
admissions is because of the interaction of the following features of
the strategy:
 A standardised VTE risk assessment is carried out on every
surgical patient at the time of admission.
 Simple risk stratiﬁcation is then used to select appropriate
prophylaxis from a menu of proven options. This provides
decision support for junior doctors.
 Prompts are in place for identifying contraindications to VTE
prophylaxis.
 Nesting the VTE protocol within a surgical clerking proforma
and using it for all adult surgical admissions provides a highly
reliable strategy. Completing the form is an essential part of the
admission process and incorporating the VTE protocol does not
interrupt work ﬂow. Risk assessment and prescription of
prophylaxis becomes the default action for clinicians (not
completing it means ‘‘opting out’’). Thus the appropriate
actions are prompted, standardised and simple.
 The proforma makes use of an accepted VTE protocol, which is
easy to use and all admissions are automatically ‘‘funnelled’’
through it.5. Limitations
Potential confounding factors and threats to the internal validity
of this study include the relatively high proportion of subjects in
each round with contraindications to prophylaxis and the fact that
some improvement could be attributed to education of medical
professionals alone. Other clinical endpoints such as rates of deep
vein thrombosis and pulmonary embolism were not addressed in
the study populations.
Guidelines already set out by NICE state that ‘‘The risk of VTE
and the risk of bleeding may change for an individual patient
several times as they progress through their hospital stay’’.8 Thus,
in addition to using this standardised protocol, individual VTE risk
during an admission needs to be re-assessed in order to maintain
optimal practice, particularly in perioperative surgical patients.
Furthermore, larger studies are needed to prove the external
validity of our results and the generalisability of these methods for
improving prescription of VTE prophylaxis in all hospitalised
G.S. McKenna et al. / International Journal of Surgery 7 (2009) 50–53 53patients. We hope this will occur soon in a different geographical
setting.6. Conclusion
Implementation of a VTE protocol as part of a clerking proforma
for acute surgical admissions is a simple and effective way of
ensuring that surgical patients receive appropriate thrombopro-
phylaxis. This strategy could be employed to broaden the scope of
the NICE guidelines to address VTE prevention in all hospitalised
patients.Acknowledgments
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